Drug Profile
Research programme: scavenger mRNA decapping enzyme inhibitors - FSMA/Repligen
Alternative Names: D 157495; Spinal muscular atrophy (SMA) programme - Repligen/PfizerLatest Information Update: 04 Nov 2017
Price :
$50
*
At a glance
- Originator Families of SMA
- Developer Families of SMA; Repligen Corporation
- Class Quinazolines
- Mechanism of Action Survival of motor neuron 1 protein stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Spinal muscular atrophy
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Spinal-muscular-atrophy in USA
- 15 Mar 2015 Repligen has patent protection for spinal muscular atrophy programme in USA (Repligen Form 10-K filed in March 2015)
- 03 Jan 2013 Repligen's spinal muscular atrophy programme (including RG 3039 and backup compounds) sub-licensed to Pfizer worldwide